Featured Research

from universities, journals, and other organizations

Combined Drug Therapy Prevents Progression Of Prostate Enlargement

Date:
December 18, 2003
Source:
NIH/National Institute Of Diabetes And Digestive And Kidney Diseases
Summary:
A combination of drugs is significantly more effective than either drug alone for preventing progression of benign prostatic hyperplasia (BPH), especially in men at high risk for disease progression, according to a study appearing in the New England Journal of Medicine tomorrow.

December 17, 2003 -- A combination of drugs is significantly more effective than either drug alone for preventing progression of benign prostatic hyperplasia (BPH), especially in men at high risk for disease progression, according to a study appearing in the New England Journal of Medicine tomorrow.

The Medical Therapy of Prostatic Symptoms (MTOPS) Trial tested whether finasteride (Proscar), doxazosin (Cardura) or a combination of the drugs could prevent progression of BPH and the need for surgery or other invasive treatments. Treatments were compared to placebo.

Physicians at 17 MTOPS medical centers treated 3,047 randomized men with BPH for an average of 4.5 years, much longer than previous studies. Vital signs, urinary symptoms, urinary flow, side effects and medication use were checked every 3 months and digital rectal exams, serum PSA and urine was checked yearly. Prostate size was measured at the beginning and end of the study by ultrasound. Progression of disease was defined by one of the following: a 4-point rise in the American Urological Association's symptom severity score, urinary retention (inability to urinate), recurrent urinary tract infection or urinary incontinence.

Finasteride, a 5 alpha-reductase inhibitor, and doxazosin, an alpha-1 receptor blocker, together reduced the overall risk of BPH progression by 66 percent compared to placebo. The combined drugs also provided the greatest symptom relief and improvement in urinary flow rate. Doxazosin alone reduced overall risk of progression by 39 percent and finasteride alone by 34 percent relative to placebo. The combination treatment and finasteride alone also significantly reduced the risk of invasive therapy by 67 percent and 64 percent, respectively. Doxazosin did not reduce the long-term risk of invasive therapy. Most invasive treatments in MTOPS were transurethral or open surgeries to remove prostate tissue. Other invasive therapy includes transurethral incision, microwave or laser therapy to reduce prostate size and prostatic stents, devices that widen the urethra.

MTOPS found that combination therapy was especially effective in men at highest risk for BPH progression-those with prostates larger than 40 ml (30 percent of participants) or serum PSAs above 4 ng/milliliter (20 percent of participants).

"The combination therapy offers dramatically greater and longer-lasting relief from symptoms and, over time, the finasteride shrinks the prostate and actually prevents growth so that fewer men at highest risk for progressive disease need surgery," said John D. McConnell, M.D., lead author of the paper. McConnell is a professor of urology and executive vice president at the University of Texas Southwestern Medical Center in Dallas.

"For the first time, MTOPS has given us benchmarks to identify men who are probably headed for surgery and may benefit most from combination therapy," said Leroy M. Nyberg Jr., Ph.D., M.D., director of urology research at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). "Men who are bothered by lower urinary tract symptoms and BPH should see their doctor about combination treatment and whether it's right for them."

BPH progressed in only 5 percent (49 men) of men on the two drugs, in 10 percent (85 men) on doxazosin, in 10 percent (89 men) on finasteride, and in 17 percent (128 men) on placebo. The events signaling disease progression were mostly worsening symptoms (78 percent), but also included acute urinary retention (12 percent) and incontinence (9 percent).

The risk of urinary retention was reduced 81 percent by combination therapy, 68 percent by finasteride alone. Doxazosin alone did not reduce the risk of urinary retention. The risk of incontinence was reduced 65 percent by combination therapy. Only 5 men developed urinary tract or blood infections. No patients developed impaired kidney function related to BPH.

"MTOPS should help alleviate the concern that medical treatment for BPH might initially relieve symptoms but mask problems related to continuing prostate growth," Nyberg said.

Twenty-seven percent of men on doxazosin, 24 percent of men on finasteride, and 18 percent of men on combination therapy stopped treatments early, primarily due to side effects. The most common side effects included sexual dysfunction in men treated with finasteride and dizziness and tiredness in men treated with doxazosin.

###

NIDDK funded the MTOPS Trial, with support from the National Center on Minority Health and Health Disparities; both are part of the National Institutes of Health. Pfizer, Inc., of New York City and Merck & Co. of Whitehouse Station, New Jersey, donated active drugs, placebos and funds for patient recruitment and retention.

Learn more about BPH at http://kidney.niddk.nih.gov/kudiseases/pubs/prostateenlargement/index.htm.


Story Source:

The above story is based on materials provided by NIH/National Institute Of Diabetes And Digestive And Kidney Diseases. Note: Materials may be edited for content and length.


Cite This Page:

NIH/National Institute Of Diabetes And Digestive And Kidney Diseases. "Combined Drug Therapy Prevents Progression Of Prostate Enlargement." ScienceDaily. ScienceDaily, 18 December 2003. <www.sciencedaily.com/releases/2003/12/031218075400.htm>.
NIH/National Institute Of Diabetes And Digestive And Kidney Diseases. (2003, December 18). Combined Drug Therapy Prevents Progression Of Prostate Enlargement. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2003/12/031218075400.htm
NIH/National Institute Of Diabetes And Digestive And Kidney Diseases. "Combined Drug Therapy Prevents Progression Of Prostate Enlargement." ScienceDaily. www.sciencedaily.com/releases/2003/12/031218075400.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins